The basal-like type lacking hormone receptors and overexpressing HER2 is often considered triple-negative breast cancer, which can only be treated with chemotherapy, and is more common in patients with BRCA1 mutations or African ancestry [24, 25]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.